Security key
70261F202
Pasithea Therapeutics Corp. - Common Stock (KTTA)
CUSIP: 70261F202
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 25,016,593
- Total 13F shares
- 29,996
- Share change
- -59
- Total reported value
- $151,569
- Price per share
- $5.06
- Number of holders
- 7
- Value change
- -$300
- Number of buys
- 3
- Number of sells
- 2
Report period
Q2 2024
Institutions
7
Top holders
7
KTTA full security history
Newer quarter: Q3 2024
Previous quarter: Q1 2024
Pasithea Therapeutics Corp. SEC filings
Pasithea Therapeutics Corp. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 70261F202
Recent filing periods:
Top shareholders of KTTA - Pasithea Therapeutics Corp. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.11%
|
27,696
|
$200,804 | — | 31 Mar 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
1,345
|
$9,751 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0%
|
608
|
$4,408 | — | 31 Mar 2024 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0%
|
250
|
$2,000 | — | 31 Mar 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
150
|
$1,095 | — | 31 Mar 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
6
|
$44 | — | 31 Mar 2024 | |
| PD Joint Holdings, LLC Series 2016-A |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,608,696
|
$1,124,348 | — | 22 Oct 2022 | |
| Eric Shahinian |
3/4/5
|
Member of 10% owner group |
—
class O/S missing
|
1,788,415
|
$770,807 | — | 28 Sep 2022 | |
| Israel Maxx Abramowitz |
3/4/5
|
Not a 10% owner |
—
class O/S missing
|
1,051,575
|
$453,229 | — | 14 Sep 2021 | |
| Dean Lazer |
3/4/5
|
Not a 10% owner |
—
class O/S missing
|
902,600
|
$389,021 | — | 14 Sep 2021 | |
| Eric Lazer |
3/4/5
|
Not a 10% owner |
—
class O/S missing
|
902,600
|
$389,021 | — | 14 Sep 2021 | |
| David Delaney |
3/4/5
|
Member of 10% owner group |
—
class O/S missing
|
227,521
|
$98,062 | — | 17 Oct 2022 | |
| Avi Geller |
3/4/5
|
Member of 10% owner group |
—
class O/S missing
|
54,644
|
$23,552 | — | 19 Aug 2022 | |
| Dr. Yassine Bendiabdallah |
3/4/5
|
Chief Operating Officer, Director |
—
class O/S missing
|
300,000
|
$129,300 | — | 14 Sep 2021 | |
| Kepos Capital LP |
13F
|
Company |
—
class O/S missing
|
334,600
|
$4,000 | — | 31 Mar 2024 | |
| Warberg Asset Management LLC |
13F
|
Company |
—
class O/S missing
|
289,868
|
$3,594 | — | 31 Mar 2024 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
—
class O/S missing
|
50,000
|
$615 | — | 31 Mar 2024 | |
| Marex Group plc |
13F
|
Company |
—
class O/S missing
|
25,000
|
$308 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
—
class O/S missing
|
13,204
|
$162 | — | 31 Mar 2024 | |
| Graeme Martin Currie |
3/4/5
|
Chief Development Officer |
—
class O/S missing
|
5,938
|
— | — | 01 Mar 2024 |
Institutional Holders of Pasithea Therapeutics Corp. - Common Stock (KTTA) as of Q2 2024
As of 30 Jun 2024,
Pasithea Therapeutics Corp. - Common Stock (KTTA) was held by
7 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
29,996 shares.
The largest 7 holders included
ADAR1 Capital Management, LLC, Tower Research Capital LLC (TRC), Royal Bank of Canada, JPMORGAN CHASE & CO, FMR LLC, UBS Group AG, and BANK OF AMERICA CORP /DE/.
This page lists
7
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
6
Q2 2024 holders
7
Holder diff
1
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.